Sign Out
This product contains potassium, thus, it should be given with caution to patients with congestive heart failure or renal failure. Caution should also be exercised when administering to patients taking potassium supplements and potassium-sparing diuretics (e.g., Spironolactone, Triamterene).
A physician should be consulted to rule out the presence of other joint diseases for which other treatments should be considered.
Glucosamine treats the underlying cause of osteoarthritis and the therapeutic effect can only be seen after 2 to 3 weeks. An analgesic/anti-inflammatory drug may be advised by a physician during the first 2 to 3 weeks of glucosamine therapy.
Administration to patients with severe hepatic or renal disease should be made under medical supervision.
Patients with type 2 diabetes and those who are overweight and have problems with glucose tolerance should have their blood glucose levels carefully monitored if they use Glucosamine since Glucosamine may increase insulin resistance.
A case of exacerbated asthma symptoms triggered after initiation of Glucosamine has been reported, although symptoms resolved after Glucosamine withdrawal. Asthmatic patients starting on Glucosamine therapy should be aware of possible worsening of asthma symptoms.
Use in Children: Glucosamine should not be administered to children and adolescents under 18 years old since safety and efficacy have not been established in this age group.
Use in the Elderly: Glucosamine should be administered with caution in elderly patients with hepatic or renal disease.
Continue with Google